Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Multiple Myeloma 2Recurrence 1Lymphoma, Mantle-Cell 1Lymphoma 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia, Large Granular Lymphocytic 1Leukemia 1Congenital Abnormalities 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1Advanced Solid Tumor 1

Interventions

Rituximab 3Peripheral Blood Stem Cell Transplantation 2Methotrexate 2Etoposide 2Dasatinib 2tipifarnib 1siltuximab 1plerixafor 1fludarabine phosphate 1Tetradecanoylphorbol Acetate 1Tacrolimus 1Sunitinib 1Sirolimus 1Radiotherapy 1Radiation 1Prednisone 1Oxycodone 1Oxaliplatin 1Moxifloxacin 1Morphine 1Microarray Analysis 1Methadone 1Leukapheresis 1Lenalidomide 1Ipilimumab 1Interleukin-6 1Indium 1Granulocyte Colony-Stimulating Factor 1Gene Expression Profiling 1Fluorescent Antibody Technique 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Leukemia, Large Granular Lymphocytic × tipifarnib × Clear all
NCT00360776 2017-04-05

Tipifarnib in Treating Patients With Anemia or Neutropenia and Large Granular Lymphocyte Leukemia

National Cancer Institute (NCI)

Phase 2 Terminated
25 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Large Granular Lymphocytic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡